mobility and decreased glottic closure; an article about someone else who lost their voice after their 2nd dose of the Moderna Covid-19 Vaccine; Vocal cord paresis; inflammatory adverse reaction; adverse laryngological reaction; acute-onset voice changes/hoarser/voice becoming more fatigued/diminished in volume; mild weakness of the left true vocal fold; This spontaneous case was reported by a consumer and describes the occurrence of LARYNGEAL OBSTRUCTION (mobility and decreased glottic closure) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced LARYNGEAL OBSTRUCTION (mobility and decreased glottic closure) (seriousness criterion medically significant), APHONIA (an article about someone else who lost their voice after their 2nd dose of the Moderna Covid-19 Vaccine), VOCAL CORD PARESIS (Vocal cord paresis), VACCINATION COMPLICATION (inflammatory adverse reaction), LARYNGEAL DISCOMFORT (adverse laryngological reaction), DYSPHONIA (acute-onset voice changes/hoarser/voice becoming more fatigued/diminished in volume) and VOCAL CORD DYSFUNCTION (mild weakness of the left true vocal fold). At the time of the report, LARYNGEAL OBSTRUCTION (mobility and decreased glottic closure), VOCAL CORD PARESIS (Vocal cord paresis), VACCINATION COMPLICATION (inflammatory adverse reaction), LARYNGEAL DISCOMFORT (adverse laryngological reaction), DYSPHONIA (acute-onset voice changes/hoarser/voice becoming more fatigued/diminished in volume) and VOCAL CORD DYSFUNCTION (mild weakness of the left true vocal fold) outcome was unknown and APHONIA (an article about someone else who lost their voice after their 2nd dose of the Moderna Covid-19 Vaccine) had resolved.            No relevant concomitant medications were reported. No treatment information was provided. Crosslink to MOD21-174332 and MOD21-174341 The videostroboscopic investigation revealed mild weakness of the left true vocal fold with decreased tensioning with phonation and also has reduced mobility and decreased glottic closure that improved with higher pitches. Patient had no prior medical history. She presented with a 2-month history of persistent complaint of sudden voice changes 3 days after receiving the second dose of the Moderna COVID-19 vaccine. She denied any recent viral illnesses and any additional symptoms.   This case was linked to MOD-2021-174332, MOD-2021-174341 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 22-Dec-2021: Follow-up received on 22-DEC-2021 contains significant information - Events added.; Sender's Comments: This is a spontaneous case concerning a 28-year-old female patient with no medical history provided, who experienced the serious unexpected event of Laryngeal obstruction(seriousness criterion medically significant),  with the non-serious unexpected events of Aphonia, Vocal cord paresis, Vaccination complication, Laryngeal discomfort, and Vocal cord Dysfunction. The patient received the second dose of mRNA-1273 (Moderna COVID-19 Vaccine) on an unknown date and experienced all serious events on an unknown date. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.